TLX News: Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer - 21st May 2024, 9:58am

[annb0t]

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under pre-clinical evaluation for multiple cancer targets. Initial results demonstrate rapid elimination from blood circulation compared to standard antibodies and hepatic (liver) clearance – both highly desirable characteristics for use with alpha em...

>>> Read more: Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer